Ultra-low Dose Contrast for Endovascular Procedures

Launched by ATTIKON HOSPITAL · Feb 15, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a very small amount of a special dye called iodinated contrast agent during a procedure aimed at improving blood flow in patients with severe leg circulation problems, specifically those who also have some kidney issues. The trial is being conducted in a new facility and aims to see if this approach is safe and effective for people with chronic limb-threatening ischemia (CLTI) and kidney function that is not at its best.

To participate in this study, you need to have been scheduled for a specific leg procedure and have certain levels of kidney function (stage 2-4 renal disease, which means your kidneys are not working as well as they should). However, if you are on dialysis, have a different stage of kidney disease, or have had allergic reactions to similar dyes, you won't be eligible. If you join the trial, you can expect to receive careful hydration before and after the procedure to help protect your kidneys. The trial is currently recruiting participants of all ages and genders who meet these criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • CLTI
• • Prescheduled infrainguinal revascularization procedure
• • Renal disease stage 2-4 (eGFR \<60ml/minute/1.73m2)
• • Adequate pre- and post-procedural hydration protocol
• Exclusion Criteria:
• • Inadequate pre- and post-procedural hydration protocol
• • End-stage renal disease/ dialysis
• • eGFR \>60ml/minute/1.73m2)
• • Endovascular treatment of Iliac artery steno-oclussive disease
• • Allergy to contrast media